Table S1.

Summary of serum binding and neutralization

				FRNT50‡
Sample	Day after fever onset*	Infection type	ZIKV endpoint dilution†	DENV2	ZIKV
31	4	DENV2	600,000	1,653	392
32	3	DENV2	5,600	1,355	294
33	5	DENV2	40,600	1,318	1,602
39	6	DENV2	819,200	2,286	770
55	4	DENV2	675,000	1,373	18,940
55R§	100		25,000	218	3,344
60	6	DENV3	302,400	7,614	60
60R§	40		150,000	14,807	126
67	6	DENV1	125,000	2,858	832
67R§	61		42,500	1,880	285
79	4	DENV1	65,600	528	23,109
79R§	37		165,000	470	50,346
86	6	DENV3	177,400	322	67
86R§	41		125,000	263	350
21		HC¶	175	<30	<30
22		HC¶	179	<30	<30

^*Number of days post-fever onset at which blood was collected.

^†IgG ELISA measuring endpoint titer for binding to ZIKV-infected lysate. The signal from mock lysate was <250 for all samples.

^‡50% focus reduction neutralization titer.

^§Convalescent sample.

^¶Healthy control.